Tag:

Gilead

Gilead to buy Arcellx for $7.8B to expand cancer therapy pipeline

Gilead Sciences (GILD) will acquire its partner Arcellx (ACLX) in a deal valued at up to $7.8 billion, marking its largest acquisition since 2020. The move aims to expand Gilead’s cancer treatment portfolio beyond its core HIV and liver disease drugs.

23 Feb 2026-17:58
Gilead to buy Arcellx in $7.8B deal

Gilead Sciences said on Monday it will acquire cancer therapy developer Arcellx in a deal valuing the company at an implied equity value of $7.8 billion.

23 Feb 2026-15:40
Gilead announces $11 billion in new investments in US

07 May 2025-22:56
Gilead, LEO Pharma partner to develop programs for inflammatory diseases

11 Jan 2025-23:47